Valcuria

Valcuria is a biotechnology company focused on developing next-generation inhibitors of Valosin-containing protein (VCP), also known as p97, a critical regulator of protein homeostasis. By targeting the AAA+ ATPase p97, the company aims to disrupt the cellular stress response and protein degradation pathways that are frequently hijacked by cancer cells and implicated in neurodegeneration. Valcuria's lead programs are designed to overcome the limitations of earlier p97 inhibitors, such as poor metabolic stability and off-target effects, to provide potent and selective therapeutic options. The company is currently advancing its pipeline through pre-clinical development for both oncology and CNS-related indications.